Why Vertex Pharmaceuticals Stock Topped the Market Today : c

The company reported that it met its primary endpoint in a study for its non-opioid pain drug.

Related Keywords

Reshma Kewalramani , Drug Administration , Vertex Pharmaceuticals , Fast Track Designations , New Drug Application , Motley Fool Stock Advisor , Stock Advisor , Acute Pain , Primary Endpoint ,